LungLifeAI Logo

Executive Directors

Paul Pagano, PhD – Chief Executive Officer

Paul Pagano is the CEO of the Company and has over 15 years of experience in the sciences covering chemistry, engineering, and cancer biology. He was trained at UCLA in translational lung cancer research and has multiple publications spanning early disease pathogenesis and resistance to targeted lung therapy.

Paul has spent the last five years at the Company leading research and development teams in developing clinical diagnostics for lung cancer using liquid biopsy. Paul has held positions at Cynvenio Biosystems Inc (formerly known as CytomX Therapeutics, Inc.) where he developed and patented a microfluidic platform for circulating tumor cell enrichment and analysis, and at Amgen Inc. in quality analytical laboratories. Prior to Amgen Inc., he worked in Human Resources at State Farm Insurance, one of the leading property and casualty insurance providers in the US, where he facilitated the California zone restructuring and consolidation efforts that resulted in significant operational cost savings.

Paul received a B.S. from UC Santa Barbara in microbiology and immunology, and earned a PhD in pharmacology from the David Geffen School of Medicine at UCLA.

David Anderson – Chief Financial Officer

David is a chartered accountant and member of the Institute of Chartered Accountants of England and Wales with over 25 years’ experience of senior finance roles. He qualified with Stoy Hayward (now BDO LLP) and from 1998 to 2009 was an audit partner in their London office before becoming an audit partner with Crowe Clark Whitehill (now Crowe UK LLP) from 2010 to 2012. Since then he has held senior finance roles with Strategic Minerals Plc, Hakkasan and C|T Group. He is currently the CFO of Verici Dx Plc.

David received a BSc(Econ) from the London School of Economics.

LungLifeAI Logo
LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.